Bayesian methods for the design and analysis of noninferiority trials

被引:16
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
下载
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [31] Bayesian methods for the design and interpretation of clinical trials in very rare diseases
    Hampson, Lisa V.
    Whitehead, John
    Eleftheriou, Despina
    Brogan, Paul
    STATISTICS IN MEDICINE, 2014, 33 (24) : 4186 - 4201
  • [32] Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690
    Ibrahim, Joseph G.
    Chen, Ming-Hui
    Chu, Haitao
    BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
  • [33] Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690
    Joseph G Ibrahim
    Ming-Hui Chen
    Haitao Chu
    BMC Medical Research Methodology, 12
  • [34] Challenges in the Design and Interpretation of Noninferiority Trials Insights From Recent Stent Trials
    Macaya, Fernando
    Ryan, Nicola
    Salinas, Pablo
    Pocock, Stuart J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (07) : 894 - 903
  • [35] Choice of δ noninferiority margin and dependency of the noninferiority trials
    Tsong, Yi
    Zhang, Joanne
    Levenson, Mark
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (02) : 279 - 288
  • [36] Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials
    Scott K. Aberegg
    Andrew M. Hersh
    Matthew H. Samore
    Journal of General Internal Medicine, 2018, 33 : 88 - 96
  • [37] Incorporating a companion test into the noninferiority design of medical device trials
    Lu, Nelson T.
    Xu, Yunling
    Yang, Ying
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (01) : 143 - 150
  • [38] Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials
    Aberegg, Scott K.
    Hersh, Andrew M.
    Samore, Matthew H.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (01) : 88 - 96
  • [39] A Bayesian approach in design and analysis of pediatric cancer clinical trials
    Ye, Jingjing
    Reaman, Gregory
    De Claro, R. Angelo
    Sridhara, Rajeshwari
    PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 814 - 826
  • [40] Practical Bayesian design and analysis for drug and device clinical trials
    Hobbs, Brian P.
    Carlin, Bradley P.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (01) : 54 - 80